A 62-year-old woman with melanoma sits forward on the stretcher, too tired to finish a sentence. Her skin is cool, her mouth dry, and she says even water makes her nauseated. She received her latest infusion nine days ago; the monitor shows a blood pressure of 82/50. The team is deciding what to draw—and what cannot wait.

— What’s your move? Read on.

Before you read
  • When should treatment begin before confirmatory testing returns?
  • Which early clues point to endocrine toxicity rather than infection?

When to Think of It

Consider an immune-related adverse event (irAE) in anyone taking or recently treated with a checkpoint inhibitor who develops new dyspnea, chest pain, diarrhea, abdominal pain, weakness, confusion, rash, or unexplained organ dysfunction. Toxicity can arise weeks to months after treatment—or after it has stopped.

Sick or Not Sick

The key fork is stable, mild symptoms versus organ-threatening disease or physiologic instability. Shock, hypoxia, chest pain, new arrhythmia, altered mental status, severe diarrhea, or rapidly worsening organ function means treat as severe while investigating competing causes.

The First Fifteen Minutes

  • If hypotensive with suspected adrenal crisis: draw cortisol and ACTH first if this causes no delay, then give hydrocortisone 100 mg IV; it replaces deficient cortisol and restores vascular responsiveness. Give 1 L isotonic crystalloid IV, then reassess perfusion and repeat as indicated.
  • If severe or rapidly progressive irAE is suspected: give methylprednisolone 1–2 mg/kg IV; suppressing immune-mediated inflammation may limit organ injury. For suspected ICI myocarditis with instability or significant cardiac injury, give methylprednisolone 1,000 mg IV daily and involve cardiology/oncology emergently.
  • If hypoglycemic: give dextrose 25 g IV (e.g., D50W 50 mL); it rapidly corrects neuroglycopenia while the cause is addressed.
  • Obtain ECG and troponin for possible myocarditis; assess oxygenation and chest imaging for pneumonitis; check electrolytes, glucose, renal/liver function, and stool studies when indicated. Do not let testing delay resuscitation.

Definitive Care & Disposition

Hold further checkpoint inhibitor doses during suspected clinically significant toxicity and contact oncology early. Admit severe or organ-threatening cases; use ICU care for shock, respiratory failure, significant arrhythmia, or rapidly evolving myocarditis. Tailor investigations to the affected organ and exclude infection, tumor progression, and other medication effects. Endocrine deficiencies may require long-term hormone replacement; persistent severe inflammation may need specialist-directed additional immunomodulation.

How This One Kills

Treating unexplained fatigue, nausea, and hypotension as routine dehydration can miss adrenal crisis; waiting for a cortisol result before giving glucocorticoid can turn a reversible emergency into refractory shock.
The Differential — What Else Looks Like This
  • Sepsis — fever, cultures, or a plausible source may support it, but infection and irAE can coexist; assuming only inflammation may delay antibiotics.
  • Tumor progression — imaging may show disease at the affected organ; mislabeling progression as toxicity can lead to harmful immunosuppression.
  • Acute coronary syndrome — ischemic ECG changes or a regional wall-motion pattern favor it; missing ICI myocarditis risks sudden arrhythmia or death.
  • Infectious colitis — stool pathogen testing may identify a cause; treating infection as immune colitis can worsen it.

The Second-Day Story

In older adults, symptoms may be limited to falls, confusion, poor intake, or a subtle rise in creatinine; after steroids or antipyretics, fever and inflammatory signs may be muted. Toxicity may also emerge well after the last infusion. Reconcile the immunotherapy history, compare with baseline function and laboratory values, and screen the organ systems suggested by the presentation rather than relying on a classic syndrome.
Back to Our Patient
Back to our 62-year-old with cool skin, nausea, and a blood pressure of 82/50: her recent checkpoint inhibitor exposure makes an irAE a bedside consideration, but shock is the call that matters most. Draw cortisol and ACTH if immediately feasible, give hydrocortisone 100 mg IV and isotonic fluid, and check glucose, electrolytes, ECG, and troponin while evaluating for infection and other causes. Her sodium is low, glucose is 58 mg/dL, and cortisol is profoundly low; she improves with resuscitation and is admitted for adrenal-crisis management and evaluation for treatment-related endocrine toxicity.
Patient Presentation to Attending
How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling
“This is a 62-year-old woman with melanoma on recent checkpoint inhibitor therapy, presenting with profound fatigue, nausea, and hypotension. She received her last infusion nine days ago and has had poor intake, but no fever, diarrhea, chest pain, dyspnea, or focal infectious symptoms. She is cool and dry, with a blood pressure of 82/50 and no respiratory distress. Glucose is 58, sodium is low, and her cortisol is profoundly low; ECG and initial troponin do not suggest myocarditis. I’m concerned for immune therapy–associated adrenal crisis, while continuing to evaluate for infection and other causes of shock. I’ve drawn endocrine studies without delaying hydrocortisone and fluid resuscitation, and I recommend admission for ongoing treatment and oncology/endocrinology evaluation.”

Study Directive

  • From memory, list five organ systems affected by checkpoint inhibitors and one emergency presentation for each.
  • Practice a 60-second approach to suspected adrenal crisis: bedside clues, time-critical labs, and treatment trigger.
  • Review your institution’s irAE grading and escalation pathway; identify whom to call for suspected myocarditis, pneumonitis, and severe colitis.

Recent Literature

  • Review or guideline Immune-Related Adverse Events of Immune Checkpoint Inhibitors
    Ramos-Casals M, Sisó-Almirall A · Ann Intern Med, 2024 · PMID 38346306 · cited 93×
    Recognize checkpoint inhibitor toxicities across organ systems early, and start appropriate evaluation and treatment before inflammation becomes life-threatening.